-
With recession-driven budget cuts being only the latest example, the field of hospital epidemiology and infection prevention has faced numerous threats and ominous predictions of its impending doom.
-
The Joint Commission is calling on health care administrators to take the lead in preventing infections with multidrug-resistant organisms (MDROs), reminding them that current patient safety goals require CEOs to take responsibility for implementing programs to prevent these deadly and costly outcomes.
-
The Joint Commission takes on the controversial issue of decolonization of patients carrying multidrug-resistant organisms (MDROs) in a new report aimed at health care CEOs.
-
National health care reform must include a quality component including preventing health care-associated infections if it is to become an effective and affordable reality, Mark R. Chassin, MD, president of The Joint Commission, notes in a commentary posted on the Joint Commission web site (http://www.jointcommission.org).
-
-
-
Polypharmacy is the simultaneous use of multiple medications. Many authors have defined polypharmacy as the simultaneous use of at least five or six medications. Others have suggested that polypharmacy should not be determined by the absolute number of medications, but rather the use of even a single medication that is not clearly indicated.
-
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.
-
This issue is the second installment in a two-part series on breast cancer. The first part covered epidemiology, histologic types of breast cancer, screening, diagnosis, principles of treatment, and surgical management. This issue will cover chemotherapy, radiation therapy, endocrine therapy, metastatic breast cancer, and primary care for the breast cancer survivor.
-
Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
